

TABLE OF CONTENTS

CONTENT	PAGE
ACKNOWLEDGEMENT	iii
ABSTRACT	v
LIST OF TABLES	xiv
LIST OF FIGURES	xv
ABBREVIATIONS	xvii
CHAPTER I: INTRODUCTION	
1.1. Statement and significance of problem	1
1.2. Literature reviews	4
1.2.1. Apoptosis pathway	4
1.2.2. Cell death defects and tumorigenesis	7
1.2.3. The inhibitor of apoptosis protein family (IAP)	9
1.2.4. Survivin: Structure & Function	11
1.2.5. Survivin in apoptosis control and cell cycle regulation	15
1.2.6. Survivin expression in normal and cancer tissues	18
1.2.7. Survivin autoantibody	19
1.2.8. The molecular basis and molecular markers for diagnosis and prognosis in colorectal, liver and lung cancer	20

1.3. Objectives	25
-----------------	----

CHAPTER II: MATERIALS AND METHODS

I. Research design	26
II. Materials and methods	27
2.1. Tissue and serum collection	27
2.2. Chemicals	28
2.3. RNA extraction	28
2.4. Calculation of total RNA concentration	29
2.5. Semiquantitative determination of survivin mRNA in tumor tissues by reverse transcriptase polymerase chain reaction (RT-PCR)	30
2.5.1. Amplification of survivin mRNA by reverse transcriptase polymerase chain reaction (RT-PCR)	30
2.5.2. Agarose gel electrophoresis	32
2.6. Detection of survivin autoantibody by avidin capture ELISA	32
2.6.1. Survivin-BCCP fusion protein	32
2.6.2. Optimization of survivin-BCCP concentration	33
2.6.3. Optimization of protein solution for blocking	34
2.6.4. Optimization of serum dilution	34
2.6.5. Optimization of secondary antibody	34
2.6.6. Determination of survivin autoantibody in serum by avidin capture ELISA	35

2.7. Detection of survivin autoantibody by flow cytometry (indirect immunofluorescence)	35
2.7.1. Titration for optimal concentration of Streptavidin beads for biotinylated survivin coating	35
2.7.2. Optimization of serum dilution	36
2.7.3. Determination of survivin autoantibody in serum by flow cytometry	36
2.8. Western blot analysis	36
2.8.1. Separation of proteins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)	37
2.8.1.1. Preparation of stacking and separating gel	37
2.8.1.2. Preparation of the sample and electrophoresis	37
2.8.2. Electrotransfer of separated protein from the gel into the blotting membrane	38
2.8.3. Immunodetection	38
2.8.4. Detection of the survivin autoantibody signal	39
2.9. Statistical analysis	40

CHAPTER III: RESULTS AND DISCUSSIONS

3.1. Patients and specimens	41
3.2. Total RNA extraction	42
3.3. Clinicopathological characteristics of the tumor tissues in different types of cancer	43

3.4. Semiquantitative determination of survivin mRNA in tumor tissues by RT-PCR	45
3.5. Optimal conditions of avidin capture ELISA for detection of survivin autoantibodies	51
3.6. Survivin autoantibody in sera by avidin capture ELISA	60
3.7. Optimal conditions of indirect immunofluorescence flow cytometry for detection of survivin autoantibody	67
3.8. Survivin autoantibody in sera by indirect immunofluorescence flow cytometry	71
3.9. Western blot analysis	74
3.10. Survivin expression in correlation to classification of clinicopathological features	80
CHAPTER IV: CONCLUSION	87
REFERENCES	88
APPENDIX	
APPENDIX A	106
APPENDIX B	109
APPENDIX C	111
APPENDIX D	118
CURRICULUM VITAE	122

LIST OF TABLES

TABLE	PAGE
2.1. Primer sequences synthesized according to Wang et al., 2003	30
3.1. Clinical characteristics of cancer patients	41
3.2. Clinicopathological characteristics of the tumor tissues	44
3.3. Summary of survivin mRNA expression in different types of tumor tissues.	50
3.4. Optical density values at 450 nm obtained by avidin capture ELISA assay using commercial survivin mAb (D8) , the sera of ten healthy normal and ten patients	64
3.5. Summary of correlation between survivin mRNA expression and clinicopathological features in colorectal, liver and lung cancer	81
3.6. The correlation between survivin mRNA expression and clinicopathological features in colorectal cancer	82
3.7. The correlation between survivin mRNA expression and clinicopathological features in liver cancer	83
3.8. The correlation between survivin mRNA expression and clinicopathological features in lung cancer	84
D1. The staging guidelines of the colorectal cancer	119
D2. The staging guidelines of the lung cancer	120
D3. The staging guidelines of the liver cancer	121

LIST OF FIGURES

FIGURE	PAGE
1.1. Apoptosis: the 'extrinsic' and 'intrinsic' pathways to caspase activation	6
1.2. IAP family members	10
1.3. Representation of survivin protein structure	13
1.4. Diagram of the protein structures for the survivin splice variants	14
1.5. The role of survivin in apoptosis pathways	16
1.6. Subcellular localization of survivin during mitosis	17
2.1. A schematic drawing of the transcripts of survivin	31
3.1. The expression of survivin in various tumor tissues was analyzed by RT-PCR	49
3.2. Survivin mRNA expression in various tumor tissues	50
3.3. Optimization of survivin-BCCP containing bacterial lysate in avidin capture ELISA	54
3.4. Determination of optimal blocking solution	55
3.5. Determination of the survivin-BCCP containing bacterial lysate concentrations when using NP blocking buffer system	56
3.6. Optimization of serum dilution in avidin capture ELISA	57
3.7. Reactivity of serum from healthy individuals (N) and cancer patients (T) in the avidin capture ELISA	58
3.8. Optimization of secondary antibody dilution	59

3.9. Systemic control of the avidin capture ELISA system	63
3.10. Survivin autoantibody between sera of cancer patients and healthy individuals by avidin capture ELISA	65
3.11. Determination of survivin autoantibody using pre-incubation method	66
3.12. Immunofluorescence analysis of the survivin autoantibody by indirect immunofluorescence flow cytometry	68
3.13. Optimization of biotinylated survivin coating onto Streptavidin Magnetic beads	69
3.14. Optimization of serum dilution of the indirect immunofluorescence flow cytometry	70
3.15. Systemic control of the indirect immunofluorescence flow cytometry system	72
3.16. Immunofluorescence analysis of the survivin autoantibody by indirect immunofluorescence flow cytometry	73
3.17. Control system of survivin autoantibody detection by Western immunoblotting	76
3.18. Analysis of survivin autoantibody by Western immunoblotting	77
3.19. Western blot analysis of survivin autoantibodies using survivin-BCCP containing bacterial lysates	78
3.20. Western blot analysis of autoantibodies against survivin using purified recombinant his-tagged survivin	79

ABBREVIATIONS

bp	base pairs
BCCP	biotin carboxyl carrier protein
BSA	bovine serum albumin
°C	degree celcius
cDNA	complementary deoxyribonucleic acid
DNA	deoxyribonucleic acid
DEPC	diethy pyrocarbonate
EDTA	ethylene diamine tetraacetic acid
ELISA	enzyme-linked immunosorbent assay
FITC	fluorescein isothiocyanate
g	gram
µg	microgram
GAPDH	gylceraldehyde-3-phosphate dehydrogenase
Igs	immunoglobulins
IgG2a	immunoglobulin subclass 2a
µl	microliter
mg	milligram
ml	milliliter
M	molar

mM	millimolar
mRNA	messenger ribonucleic acid
ng	nanogram
NP-40	nonidet p-40
OD	optical density
PBS	phosphate buffer saline
RNA	ribonucleic acid
RT-PCR	reverse transcriptase polymerase chain reaction
SDS-PAGE	sodium dodecyl sulfate-polyacrylamide gel electrophoresis
TBE	tris-Borate-EDTA
TMB	tetramethyl benzidine